<DOC>
	<DOCNO>NCT00606437</DOCNO>
	<brief_summary>Results date umbilical cord blood transplantation adult fully mature adolescent patient inferior see child , due low stem cell dosage adult toxic condition regimen . This phase 1 protocol use potentially less toxic bone marrow condition regimen , follow infusion combine umbilical cord blood graft provide patient high stem cell dose give single umbilical cord blood infusion . The subject condition total body irradiation ( TBI ) 13.5 Gy fludarabine . Following conditioning , two unrelated , partially match umbilical cord blood graft infuse provide minimum nucleated cell dose 3 x 10e7/kg . The primary objective study measure frequency treatment-related toxicity engraftment .</brief_summary>
	<brief_title>Total Body Irradiation With Fludarabine Followed Combined Umbilical Cord Blood ( UCB ) Transplants</brief_title>
	<detailed_description>Results date umbilical cord blood transplantation adult fully mature adolescent patient inferior see child . There two reason . First stem cell dose , measure nucleated cells/kg body weight , considerably low due size recipient . This result high incidence graft failure , delayed engraftment , impaired immune reconstitution . Multiple study suggest nucleated cell dose 1.5 2 x 107/kg result unacceptably high risk graft failure . Only minority adult patient suitably match umbilical cord blood unit contain 1.5 x 107 nucleated cells/kg . The second reason inferior outcome umbilical cord blood transplantation adult patient comparison child , conventional myeloablative bone marrow conditioning regimens toxic . This phase 1 protocol use potentially less toxic bone marrow condition regimen , follow infusion combine umbilical cord blood graft provide patient high stem cell dose give single umbilical cord blood infusion . The subject condition TBI 13.5 Gy fludarabine . Fludarabine pharmacokinetics measure correlated kinetics donor cell engraftment well frequency treatment-related toxicity . Following conditioning , two unrelated , partially match umbilical cord blood graft infuse provide minimum nucleated cell dose 3 x 10e7/kg . The primary objective study measure frequency treatment-related toxicity engraftment .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age 14 65 year . Available cord blood graft . Patients high risk ALL first complete remission , high risk define presence ( 4 ; 11 ) , ( 9 ; 22 ) ( 1 ; 19 ) patient present extreme hyperleukocytosis ( WBC &gt; 500,000/ul ) partial remission induction therapy . Adult patient acute nonlymphocytic leukemia ( ANLL ) first complete remission highrisk cytogenetics ( monosomy chromosome 5 7 , del ( 5q ) , abn ( 3q26 ) , complex karyotypic abnormality ) failure achieve complete remission standard induction therapy . All patient ALL ANLL second subsequent remission partial remission . All patient CML chronic ( failed interferon and/or Gleevec ) accelerate phase . Patients myelodysplastic syndrome International Prognostic Scoring System ( IPSS ) risk category INT1 great . Patients severe aplastic anemia must fail immunosuppressive therapy cyclosporine plus antithymocyte globulin . NonHodgkin 's lymphoma Hodgkin 's disease : High risk disease first complete partial remission Chemotherapyresistant relapse Second subsequent relapse remission Myelofibrosis myeloid metaplasia . High risk , congenital immunodeficiency disorder result recurrent ( &gt; 3 episode ) lifethreatening infection , know curable allogeneic stem cell transplantation ( include , limited ; severe combine immunodeficiency disorder , combine immunodeficiency disease , WiskottAldrich syndrome , ChediakHigashi syndrome , chronic granulomatous disease , leukocyte adhesion deficiency , hemophagocytic lymphohistiocytosis ) . Patients history CNS disease must treat active CNS disease time protocol treatment . ECOG performance status &lt; equal 2 . Patients must adequate function organ system measure : Creatinine clearance ( Cockcroft Gault equation ) &gt; equal 30 ml/min . Hepatic transaminase ( ALT/AST ) &lt; equal 4 x normal , bilirubin &lt; equal 2.0 mg/dl Pulmonary function test demonstrate FVC FEV1 &gt; equal 50 % predict age DLCO &gt; equal 50 % predicted Ejection fraction &gt; equal 45 % echocardiogram , radionuclide scan cardiac MRI Patients must HIV negative . They HLAABC/DR identical related bone marrow UCB donor . They NOT 5/6 antigen match related bone marrow UCB donor . Their condition precludes wait search find donor National Marrow Donor Registry 8/8 ( HLAA , B , C , DRB1 ) antigen high resolution ( allelelevel ) type match unrelated donor find . Patients must pregnant . Patients circulate antibody specific donor major histocompatibility antigen ( determined panel reactive antibody assay ) . Patients progressive ANLL ALL follow second thirdline treatment regimen .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Umbilical Cord Blood Graft</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>